Exciting Investor Conferences Ahead for Catalyst Pharmaceuticals
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX), a dynamic biopharmaceutical company, is preparing to showcase its pioneering efforts in developing treatments for rare and hard-to-treat diseases. With a focus on in-licensing and commercializing novel therapeutics, Catalyst is making significant strides in the medical community.
Key Presentations Planned
As part of its commitment to maintaining transparency and engaging with investors, the President and CEO of Catalyst, Richard J. Daly, along with select members of the management team, will be attending several high-profile investor conferences in the upcoming weeks.
Wells Fargo Healthcare Conference Details
The first on the calendar is the Wells Fargo Healthcare Conference. Scheduled for September 3, 2025, Catalyst will be presenting at 2:15 PM ET. This conference presents a valuable opportunity for the company to connect with key stakeholders in the healthcare sector.
Cantor Global Healthcare Conference Insights
Another notable event is the Cantor Global Healthcare Conference on September 4, 2025, at 3:20 PM ET. Catalyst will provide insights into its ongoing projects and future direction, reinforcing its commitment to addressing urgent healthcare needs.
H.C. Wainwright Global Investment Conference
On September 8, 2025, Catalyst will be present at the H.C. Wainwright 27th Annual Global Investment Conference, with a presentation set for 9:00 AM ET. This event is anticipated to foster meaningful discussions on the company’s financial outlook and potential growth strategies.
Baird Global Conference Highlights
The Baird Global Conference on September 9, 2025, at 12:50 PM ET, rounds out the series of conferences Catalyst will attend. Each of these forums is crucial for displaying Catalyst's work and garnering interest from the investment community.
Accessing Conference Webcasts
For those interested in tuning in, webcasts from these conferences will be accessible through the Investor Relations section of Catalyst's official website. Highlights and replays will be available for a minimum of 30 days following the events, ensuring that stakeholders can remain informed on Catalyst’s developments.
About Catalyst Pharmaceuticals
Founded with a mission to enhance the quality of life for individuals with rare diseases, Catalyst Pharmaceuticals, Inc. has established itself as a leader in the biopharmaceutical industry. The company is recognized for its unwavering dedication to patient care and strives to make essential treatments accessible to those who need them most. The headquarters in Coral Gables plays a pivotal role in its operations and commercial strategies.
In recent accomplishments, Catalyst was highlighted on prestigious lists, including Forbes' ranking of America’s Most Successful Mid-Cap Companies and the Deloitte Technology Fast 500™ as one of North America's Fastest-Growing Companies.
Contact Information
For further inquiries, investors can reach out to:
Investor Contact:
Mary Coleman, Catalyst Pharmaceuticals, Inc.
(305) 420-3200
IR@catalystpharma.com
Media Contact:
David Schull, Russo Partners
(858) 717-2310
david.schull@russopartnersllc.com
Frequently Asked Questions
What is Catalyst Pharmaceuticals known for?
Catalyst Pharmaceuticals focuses on developing treatments for rare and difficult-to-treat diseases.
When will Catalyst participate in investor conferences?
Catalyst will participate in several conferences throughout September 2025, with presentations on different dates.
How can I access Catalyst's conference webcasts?
Webcasts will be available in the Investor Relations section of Catalyst’s website for at least 30 days after each event.
Who should I contact for investor inquiries?
Mary Coleman from Catalyst's team is the designated contact for investor inquiries.
What recognition has Catalyst received recently?
Catalyst has been recognized on lists highlighting successful mid-cap companies and fastest-growing technology firms.
